-
Featured Authors
-
Archives
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: health
Curative Therapies: Aligning Policy with Science to Ensure Patient Access
New hepatitis C medications with exceptionally high cure rates have significantly improved treatment, while also posing a challenge for the healthcare system because the cost of the medications are higher in the short run than other medications. As more curative therapies for different conditions come to market, the healthcare system will need to manage the concentration of upfront expenses in a sustainable manner. A Super Session panel at the 2016 BIO International Convention examined this Read More >
Facts Not Fiction: Digital Delivers Results for Biotech Companies
A panel of experts in the digital advertising space assembled Wednesday at the 2016 BIO International Convention to discuss how biotech companies can utilize digital advertising in their overall marketing strategies. The session was moderated by Julie Papanek, (Principal, Canaan Partners), and the panelists were: Craig Hashi, Ph.D. (Health, Facebook), Matthew Howes (Executive Vice President, Strategy & Growth, PALIO, an inVentiv Health company), Will Springgate (Director, Life Sciences Allscripts), and Wister Walcott (Co-Founder; Lead Consultant, Marin Software; Proxita). The Read More >
Antibiotic Development Incentives May Be Tricky to Implement
A recently proposed broad suite of antibiotic development incentives has received strong support from industry stakeholders, but revealed a desire to move specific ideas and proposals into practice and skepticism about so-called “pay-or-play” provisions during a Wednesday morning panel at the BIO International Convention. Reflecting the increasing importance of the topic, the discussion was one of three panels devoted to the serious global threat of antimicrobial resistance, noted the World Health Organization’s Martin Friede, compared Read More >
Janet Napolitano and Jim Greenwood Talk Innovation, Homeland Security, and Politics at #BIO2016 Fireside Chat
Janet Napolitano, President of the University of California, emphasized the need for research at every level, while also touching upon homeland security issues like the Zika virus and the current presidential election during a fireside chat yesterday with Jim Greenwood at the 2016 BIO International Convention. At the University of California “we teach for California, but we research for the world,” Napolitano explained to Greenwood when he asked about the challenges the university faced in Read More >
Achieving Healthcare Sustainability: Can we Move from “Value” to “Predictability”?
Drug costs are one of largest healthcare concerns across the American political spectrum. But drug costs, pricing, spending and value are not the same thing, panelists emphasized during the BIO International Convention Tuesday afternoon. Session moderator Susan Garfield, principal at EY, challenged herself to refrain from using the term “value,” to foster a discussion about “predictability:” if we can better predict outcomes, can we better allocate healthcare resources? The challenge is that innovation breeds a lot of Read More >
